🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai East Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanghai East Hospital as lead sponsor. Synced 26 Sep 2026
25Current trials
16Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai East Hospital is the lead sponsor of 25 current clinical trials in our China register. 16 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Albumin, Cisplatin and Henagliflozin. The most-studied condition is Stroke.

ClinicalTrials.gov trials by status

  • Recruiting1664%
  • Not yet open624%
  • Active, closed28%
  • By invitation14%

Trials by phase

  • Observational832%
  • Not applicable728%
  • Phase EARLY_PHASE1312%
  • Phase 128%
  • Phase 328%
  • Phase 228%
  • Phase 1/214%
01

Clinical trials sponsored by Shanghai East Hospital

25 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal Cancer
NCT06446050 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer
Phase EARLY_PHASE1 Recruiting 2023-06 China
Biomarkers Based EArly Diagnosis of STroke Subtype Cohort(Bio-EAST)
NCT07003477 · ClinicalTrials.gov ↗ · Stroke
Observational Recruiting 2025-06 China
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
NCT06072989 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2023-10 China
Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial
NCT06773364 · ClinicalTrials.gov ↗ · Suspected Stroke
Phase 3 Recruiting 2025-04 China
A Clinical Trial of Parkinson's Disease Treatment by HiPSCs Derived Dopaminergic Neural Precursor Cells
NCT06145711 · ClinicalTrials.gov ↗ · Parkinson's Disease
Not applicable Recruiting 2023-11 China
Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
NCT06765564 · ClinicalTrials.gov ↗ · ALS
Not applicable Recruiting 2024-03 China
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
NCT07002476 · ClinicalTrials.gov ↗ · Stroke
Phase 3 Recruiting 2025-06 China
Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management
NCT07279259 · ClinicalTrials.gov ↗ · Stroke, Acute Ischemic Stroke, Thrombolysis
Phase 2 Recruiting 2026-01 China
HUC-MSC for Treatment of High-risk HPV Infection
NCT06610773 · ClinicalTrials.gov ↗ · Human Papillomavirus Viruses, Mesenchymal Stem Cells
Phase 1/2 Recruiting 2024-03 China
An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT06939569 · ClinicalTrials.gov ↗ · Inflammatory Bowel Disease (IBD), Metabolic Dysfunction Associated Fatty Liver Disease
Observational Recruiting 2025-05 China
A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR
NCT06712862 · ClinicalTrials.gov ↗ · Ischemic Heart Disease
Observational Recruiting 2025-12 China
A Cohort Study on Early Stages of Heart Failure
NCT06673615 · ClinicalTrials.gov ↗ · Stages of Heart Failure
Observational Recruiting 2024-04 China
A Preliminary Clinical Study Protocol for Evaluating the Efficacy and Safety of Pulse Electric Field Ablation Systems in Treating Adult Type 2 Diabetes Mellitus With Suboptimal Drug Control
NCT07678866 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)
Observational Recruiting 2026-06 China
Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases
NCT07063043 · ClinicalTrials.gov ↗ · Cardiovascular Diseases (CVD)
Observational Recruiting 2024-12 China
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
NCT07463287 · ClinicalTrials.gov ↗ · MASH - Metabolic Dysfunction-Associated Steatohepatitis
Observational Recruiting 2025-04 China
MRI-Assisted Guidance for Non-Essential Tissue Sampling
NCT07516223 · ClinicalTrials.gov ↗ · PSA Progression, PSA
Not applicable Recruiting 2026-04 China
A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma
NCT07778368 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC)
Phase 2 Not yet open 2026-09 China
Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing
NCT07290816 · ClinicalTrials.gov ↗ · Intestinal Polyps
Not applicable Not yet open 2025-12 China
Effect of In-Place Slow Jogging on Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT06994234 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatotic Liver Disease
Not applicable Not yet open 2025-06 China
Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR
NCT07294495 · ClinicalTrials.gov ↗ · HCM - Hypertrophic Cardiomyopathy
Not applicable Not yet open 2026-01 China
Autonomous Regulatory Monocytes (OPM Cells) for the Treatment of Diabetic Foot in a Single-arm Open-label Clinical Study
NCT06621303 · ClinicalTrials.gov ↗ · Diabetic Foot Ulcer
Phase EARLY_PHASE1 Not yet open 2024-10 China
hucMSCs Exosomes for the Treatment of Active Ulcerative Colitis
NCT06853522 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)
Drug: Albumin
Phase EARLY_PHASE1 Not yet open 2025-05 China
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
NCT06924697 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2, Nicotine Dependence, Cigarettes
Not applicable By invitation 2025-06 China
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis
NCT06913699 · ClinicalTrials.gov ↗ · Non-alcoholic Fatty Liver Disease (NAFLD)
Observational Active, closed 2024-04 China
A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors
NCT05621486 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Active, closed 2022-09 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai East Hospital trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai East Hospital trials

28 conditions
Stroke3Advanced Solid Tumor2Advanced Colorectal Cancer1Suspected Stroke1Parkinson's Disease1Non-alcoholic Fatty Liver Disease (NAFLD)1ALS1Oral Squamous Cell Carcinoma (OSCC)1Acute Ischemic Stroke1Thrombolysis1Human Papillomavirus Viruses1Mesenchymal Stem Cells1Intestinal Polyps1Inflammatory Bowel Disease (IBD)1Metabolic Dysfunction Associated Fatty Liver Disease1Diabetes Mellitus, Type 21Nicotine Dependence, Cigarettes1Metabolic Dysfunction-Associated Steatotic Liver Disease1Ischemic Heart Disease1HCM - Hypertrophic Cardiomyopathy1Stages of Heart Failure1Type 2 Diabetes Mellitus (T2DM)1Diabetic Foot Ulcer1Ulcerative Colitis (UC)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2516

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Stroke

SponsorTrials
Xuanwu Hospital, Beijing8
Qilu Hospital of Shandong University7
Magnetic Tides2
The Second Hospital of Anhui Medical University2
The Hong Kong Polytechnic University2
The Second Affiliated Hospital of Kunming Medical University2
Duke Kunshan University2
Occlutech International1
Shanghai MicroPort Medical (Group)1
Christian Medical College and Hospital, Ludhiana, India1

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai East Hospital trials

How many clinical trials does Shanghai East Hospital sponsor?

Shanghai East Hospital is the lead sponsor of 25 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai East Hospital trials recruiting?

Yes. 16 of its 25 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai East Hospital testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Albumin (1), Cisplatin (1), Henagliflozin (1), Levetiracetam (1) and Sacituzumab Govitecan (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.